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ABSTRACT 
 
Efficient VEGF gene expression using hypoxia-inducible 
neuron-specific vector system 
 
Yeomin Yun 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Yoon Ha) 
 
 
 
Since neurons play a critical role in the central nervous system, neuron-target 
gene expression system is important for gene therapy. Ischemic neurons 
following injury affect disruption of neurovascular unit which is mediated by 
astrocyte. Also reactive astrocyte contributes to astrogliosis that aggravate 
traumatic environment. Therefore, controllable gene expression system that 
expressed in neurons selectively more than glial cells and other cell types is 
necessary. We used neuron-specific enloase (NSE) promoter to target neurons. 
NSE is one of glycolytic isoenzymes and abundant in adult brain neurons due to 
their characteristics of expression in matured neurons. Because NSE is 
expressed high in various neuronal cell types, we can design neuron-target gene 
expression system using NSE promoter. Also, to improve gene expression under 
hypoxic ischemic environment like spinal cord injury (SCI), the combination of 
erythropoietin (Epo) enhancer and NSE promoter was used. Vascular 
endothelial growth factor (VEGF) is an angiogenic peptide and has 
neuroprotective effects as well as angiogenesis. VEGF is considered good 
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therapeutic gene because it protects injured neurons and promotes sprouting of 
blood vessels to support cell survival. In this study, the use of NSE promoter 
increases the expression of luciferase reporter gene and VEGF gene. The 
luciferase and VEGF gene expression is the highest with the plasmid vector 
including Epo enhancer under hypoxic conditions and also showed proliferation 
effect. With this hypoxia-inducible neuron-specific gene expression system, 
applied gene or cell therapy is promising to regenerate SCI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------------------------- 
Key words : Neuron-specific enolase, neuron promoter, erythropoietin, 
hypoxia-inducible, tissue-specific, vascular endothelial growth factor 
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I. INTRODUCTION 
 
Physical and mechanical injury to spinal cord results in neurologic disability 
and complete loss of function. Following traumatic primary spinal cord injury 
(SCI), a cascade downstream of events occur called secondary injury. 
Secondary injury including ischemia, neuronal apoptosis, demyelination, scar 
formation exacerbates injury severity during excitotoxicity, imflammatory 
response, free radical production.1-3 Posttraumatic ischemic response is caused 
by hemorrhage, vasospasm, thrombosis of blood vessels1 and develops 
microvascular damage in spinal cord. Neuron doesn’t directly contact blood 
vessels but sensitive enough to ischemic condition and vulnerable.4 Hypoxia is 
an important component in SCI treatment and related to blood vessel condition, 
vascular endothelial growth factor (VEGF) has been proposed a potent 
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therapeutic gene due to angiogenesis its original function. Angiogenic effect of 
VEGF supports neuron survival by restoring blood supply.5,6 VEGF has 
neurotrophic and neuroprotective activity so that promote cell survival and 
blood vessel formation through high-affinity binding with phosphotyrosine 
kinase receptor.7 Since VEGF is induced to express by hypoxia-inducible 
factor-1 (HIF-1) which is activated in ischemic condition,8 ischemia should be 
necessary for VEGF expression. However, ischemic conditions following SCI 
trigger reperfusion that causes injury.9 Although VEGF has various therapeutic 
effect, VEGF expression in normal tissue is associated with tumor formation.10 
At the injury site, reactive astrocyte induces astrogliosis that intensified SCI 
mediated by expressing VEGF. With ischemic neuron following injury, VEGF 
presents negative effect that result in disruption of neurovascular unit.11 For 
these reasons, therapeutic VEGF expression should be regulated in ischemic 
neuron not normal tissue or non-neuronal cells. In order to express VEGF in 
neurons, we used neuron-specific promoter system and regulated in 
transcriptional level. Neuron-specific enolase (NSE) is one of glycolytic 
enzymes and abundant in matured neuron.12 NSE level is very low in embryonic 
brain and appears in accordance with neurogenesis. Its endogenous mRNA and 
protein is higher in differentiated state and rare in other cells, undifferentiated 
neurons.13,14 On the other hands, NNE level is high in embryonic brain and 
decrease with neuronal maturation. For these reasons, NSE is used as a marker 
protein of matured neurons. Using these characteristics, NSE promoter can be 
useful tool for target neuronal cells. In order to overexpress therapeutic gene in 
hypoxic condition and avoid express in normal tissue, erythropoietin (Epo) 
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enhancer was used. Epo gene is induced in hypoxic condition and Epo enhancer 
is well known for specific expression under hypoxic condition.15,16 In this study, 
we constructed Epo enhancer-NSE promoter combined vector system. Using 
luciferase reporter gene, we evaluated hypoxia-inducible neuron-target gene 
expression in vitro and in vivo. Furthermore, substituted VEGF was used to test 
gene expression. 
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II. MATERIALS AND METHODS 
 
1. Plasmid construction 
pSV-Luc, pNSE-Lus, pEpo-SV-Luc, pSV-VEGF-pGL3-promoter was kindly 
provided by professor Minhyung Lee of Hanyang University. Epo cDNA was 
amplified by PCR (Hotstart pfu PCR PreMix, bioneer, Daejeon, Korea) using 
pEpo-SV-AP (Lab DNA stock). Two Epo fragments are used to construct 
pEpo-NSE-Luc. First, the primers for PCR are 5’- MluI-Epo, 3’- 
NheI-AscI-Epo (Table 1). Amplified one Epo enhancer was inserted into the 
MluI and NheI site upstream of NSE promoter. Second PCR of Epo enhancer 
was conducted using primers 5’- KpnI-SpeI-EcoRV-Epo, 3’- SacI-PmeI-Epo. 
PCR products of Epo were inserted into KpnI and SacI.  
To construct pSV-VEGF, pNSE-VEGF, pEpo-NSE-VEGF, luciferase gene was 
removed from pSV-Luc, pNSE-Luc, pEpo-NSE-Luc. VEGF fragment including 
poly-A from pSV-VEGF-pGL3-promoter was introduced to luciferase location 
at HindIII and BamHI site. The plasmids were amplified in E.coli DH5α and 
purified using plasmid maxi prep kit (Qiagen, Hilden, Germany). The quantity 
of plasmids was measured using nanodrop (ND-1000, Thermo Fisher Scientific, 
Wilmington, DE, USA) by measuring the absorbance of plasmids at 260nm. 
The ratio of absorbance at 260nm and 280nm was used to assess the purity of 
DNA
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Table 1. Primers and PCR conditions for plasmids construction 
 
primer sequences 
5’- MluI-Epo CCCACGCGTGCCCTACGTGCTGTC 
3’- NheI-AscI-Epo AAAGCTAGCGGCGCGCCCGCCGGTAGGT 
5’- KpnI-SpeI-EcoRV-Epo TAT GGTACC ACTAGT GATATC GCCCT ACGTG 
3’- SacI-PmeI-Epo AAAGAGCTCGTTTAAACCGCCGGTAGGT 
step temperature time No. of cycles. 
Pre-incubation 95℃ 5 min 1 
Denaturation 95℃ 30 sec 
35 Annealing 65℃ 30 sec 
Extension 72℃ 1 min 
Final-Extension 72℃ 5 min 1 
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2. In vitro transfection 
The mouse neural stem cells (mNSC; CRL-2925, ATCC, Manassas, VA, 
USA) were maintained in Dulbecco's Modified Eagle Medium:Nutrient 
Mixture F-12 (DMEM ⁄ F-12; Gibco, Grand Island, NY, USA) supplemented 
with 10% fetal bovine serum (FBS; Thermo Scientific HyClone, Logan, UT, 
USA), 1% penicillin streptomycin (P/S; Gibco, Grand Island, NY, USA). The 
mNSCs were seeded at a concentration of 1x105/well into 6-well plates. Cells 
were cultured under normoxia conditions at 37℃ in 5% CO2. After 24 hours, 
plasmids (2μg/well) were transfected with polyethylenimine (PEI, 25000 D; 
Sigma Aldrich, St. Louis, MO, USA). PEI is a gene delivery vector for 
plasmids transfection. PEI/cDNA complexes were prepared at the ratio of 5:1 
N/P and added to cells with serum-free medium for 4 hours at 37℃ in 5% 
CO2. After 4 hours, cells were cultured under normoxia (20% O2) or hypoxia 
(1% O2) conditions for 48 hours.  
3. Cell differentiation 
For differentiation, mNSCs were seeded into 6-well plates (1x105/well) 24 
hours prior to treat retinoic acid (RA; Sigma, St. Louis, MO, USA) with 
culture medium. The culture medium was exchanged to differentiation 
medium containing DMEM/F12, 1% FBS, 1% nonessential amino acids 
(NEAA, Gibco, Grand Island, NY, USA), 0.5% P/S and 1μM RA. Neuronal 
differentiation is induced by 1μM RA for 7days. Differentiation medium was 
changed every two days. After 5 days, differentiated cells were transfected 
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and cultured for 48 hours under normoxia or hypoxia conditions. At that time, 
differentiation medium was exchanged to transfection medium (DMEM/F12, 
1% P/S). After 2 days of transfection, cells were fixed with 4% 
paraformaldehyde (PFA; Millipore, Darmstadt, Germany) for 
immunocytochemistry or lysed with reporter lysis buffer (Promega, Madison, 
WI, USA) for luciferase assay.  
For Pheochromocytoma 12 (PC12) cells differentiation, 3x105/well was 
seeded into poly-L-lysine (Sigma Aldrich, St. Louis, MO, USA) coated 6-well 
plates. PC12 culture medium is Roswell Park Memorial Institute 1640 (RPMI 
1640; Gibco, Grand Island, NY, USA) supplemented with 10% FBS, 1% P/S. 
After 24 hours, 100ng/μl nerve growth factor (NGF; R&D System, 
Minneapolis, MN, USA) was added with serum-free medium (RPMI 1640, 
1% P/S). Differentiation medium was exchanged every 2 days. pDNA 
transfection was conducted after 5 days of treating NGF and cultured another 
48 hours. 
4. Luciferase assay 
To compare the effect of promoter with or without enhancer, luciferase 
reported gene was used. Cells transfected with pSV-Luc, pNSE-Luc, 
pEpo-NSE-Luc were allowed to express luciferase in normoxia or hypoxia. 
After 48 hours and lysed with 300μl of reporter lysis buffer and undergo one 
freeze-thaw cycle. The lysates were transferred to a 1.5ml tube and 
centrifuged at 12000 rpm for 2 minutes. The supernatant lysates were 
transferred to a fresh 1.5ml tube and protein concentration was measured 
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using BCA kit (pierce, Rockford, IL, USA). Luciferase activity was 
determined by Microplate luminometer (Berthold, Bad Wildbad, Germany) in 
terms of relative light units (RLU) per milligram of total protein. 
5. Luciferase expression imaging 
 In vivo imaging system (IVIS; Xenogen, Alameda, CA, USA) was used to 
confirm luciferase expression in mNSCs transfected pSV-Luc, pNSE-Luc. 
mNSCs were seeded into 6-well plates (1x105/well) 24 hours prior to 
transfection. After 48 hours plasmids transfection as previous protocol, IVIS 
was conducted using Living Image (Xenogen). Substrate D-luciferin 
(150μg/ml) was added and bioluminescence was measured after 2-3 minutes. 
6. Reverse transcriptase polymerase chain reaction 
Total RNA was isolated from normoxia or hypoxia cultured mNSCs using 
RNeasy Plus Mini kit (Qiagen, Hilden, Germany). The extracted RNA was 
treated with RNase-free water. The concentration of RNA was measured by 
measuring the absorbance at 260nm. Isolated RNA was converted to cDNA 
using RT PreMix (bioneer, Daejeon, Korea). The PCR amplification was 
performed with 1μg of cDNA as follows : preincubation (95℃ for 5 min), 35 
cycles of PCR (95℃ for 30 sec, 59℃ for 30 sec, 70℃ for 30 sec) and 
extension (70℃ for 10 min). The specific primer sequences were VEGF 
5'-CCCAAGCTTGAAACCATGAACTTGCT-3' (forward), 
5'-GCTCTAGATCATTCATTCATCACCGCCT-3' (reverse). The PCR 
11 
 
products were separated using electrophoresis on 0.8% agarose gels. 
7. Enzyme-linked immunosorbent assay 
Cells were transfected with pNSE-VEGF, pEpo-NSE-VEGF under normoxia 
or hypoxia conditions. Cell culture supernates was collected in a 1.5ml tube 
and stored in -20℃ until used. The VEGF expression was measured by 
ELISA kit (Abfrontier, Seoul, Korea) in accordance with the manufacturer’s 
protocol.  Sample volume of 100μl was added to the designed wells 
precoated with VEGF specific monoclonal antibodies and incubated at 37℃ 
for 90 min. After discard the contents, added 0.1ml of biotinylated VEGF 
antibodies into each well and incubated at 37℃ for 60 min. Wash the plate 
three times with 0.01M PBS. Prepared ABC working solutions was added into 
each well and incubated at 37℃ for 30 min. After 5 times of wash the plate, 
90μl TMB color developing agent was added and incubated 25℃ in dark for 
20 min. After incubation period, TMB was catalyzed and changed into yellow 
color by TMB stop solution. The density of yellow was measured at 490nm.  
8. Immunocytochemistry 
 For immunostaining, plates were coated with 0.1% gelatin for 1 hour. 
mNSCs were seeded in the density of 1x105. Cells were differentiated for 
5days and transfected with pNSE-Luc. For differentiation, RA concentration 
was diluted to 1μM, 0.1μM, 0.01μM gradually. Two days after transfection, 
cells were fixed with 4% PFA and washed with 0.3% TritonX-100. Fixed cells 
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were blocked with 10% NDS, 0.3% TritonX-100 in PBS at room temperature 
for 1 hour. Cells were immunostained using anti-Luc (1:1000, Sigma, St. 
Louis, MO, USA), anti-microtubule-associated protein-2 (MAP-2; 1:500, 
Abcam, Cambridge, UK) antibodies. Confocal images were obtained with 
confocal microscopy (Carl Zeiss LSM-700, Jena, Germany). 
9. In vitro cell proliferation assay 
 mNSCs were plated in 96-well with a density of 2x103/well and followed by 
incubation for 24 hours. pEpo-NSE-luc was transfected with the same 
protocol as previous state. Cells were incubated under normoxia or hypoxia 
conditions. Cell proliferation was measured by MTT assay every day at 24 
hours interval. 5mg/ml MTT solution was added to each well, followed by 4 
hours incubation at 37℃. The reaction was stopped by removing the MTT 
solution and added DMSO to dissolve formazan crystals. VersaMax ELISA 
Microplate Reader (Molecular Device, Sunnyvale, CA, USA) tested 
absorbance 490nm value. 
10. Construction of spinal cord injury model 
To investigate whether VEGF exhibits neuroprotective effect, plasmids were 
introduced to spinal cord injury site for gene therapy. The Animal Care and 
Use Committee of the Medical Research Institute of Yonsei University 
College of Medicine approved all protocols. All procedures were performed 
according to international guidelines on the ethical use of animals, and the 
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number of animals used was minimized. Laminectomy was performed at T9 
level in adult male Sprague-Dawley rats (200-250g; OrientBio, Gyeonggi-do, 
Korea). After anesthesia (100mg/kg ketamine, Yu-han, Seoul, Korea), exposed 
spinal cord T9 level was injured by clip compression (40g; Biemer, Irvine, CA, 
USA) for 10 minutes. Plasmids (20μg) were directly injected into caudal to 
spinal cord injury site using Hamilton syringe (Hamilton, Reno, NV). 
Experimental animals were divided into four groups: PBS control (10μl), 
pSV-Luc, pNSE-Luc, pEpo-NSE-Luc, later, VEGF gene was used instead of 
luciferase gene. 
11. Tissue extraction 
 Spinal cord tissues were obtained by heart perfusion with saline (pH 7.5) and 
4% paraformaldehyde at 2 days after plasmids injection. Obtained tissues 
were homogenized with Pro-prep (iNtRON biotechnology, Gyeonggi-do, 
Korea) and lysed for 1 hour in ice. Lysed tissues were spin down and collect 
supernatant. Luciferase expression was measured as previous state in 
luciferase assay.  
12. Statistical analysis 
Data are analyzed using student’s t-test to compare between two 
experimental groups. One-way anova was used to compare data among three 
experimental groups. P-value under 0.05 was considered to be statistically 
significant.  
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III. RESULTS 
1. Construction of hypoxia-inducible neuron-specific gene 
expression plasmids. 
For neuron-specific gene expression, we constructed pSV-luc, pNSE-Luc, 
pEpo-NSE-Luc (Figure 1). Unlike SV promoter that commonly used in 
expression vector 17,18, NSE promoter could achieve transcriptional regulation 
in neuronal cells. Expression efficiency of vector including SV promoter or 
NSE promoter was assessed with the expression level of luciferase reporter 
gene. In addition to tissue targeting promoter, Epo enhancer was used to 
expression. Because of ischemic microenvironment following spinal cord 
injury, hypoxia inducible gene expression system increases the luciferase 
expression. Luciferase fragment from pSV-Luc, pNSE-Luc, pEpo-NSE-Luc 
was further replaced the VEGF therapeutic gene, leading to the construction 
of pSV-VEGF, pNSE-VEGF, pEpo-NSE-VEGF. 
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Figure 1. Structure of pSV-Luc, pNSE-Luc, pEpo-NSE-Luc plasmids. The 
pSV-Luc contains simian virus 40 promoter. The pNSE-Luc contains 
neuron-specific enolase promoter. The pEpo-NSE-Luc has two copies of Epo 
enhancer upstream of NSE promoter. 
16 
 
2. Luciferase expression in various neuronal cells. 
In vitro transfection assay was performed to compare the promoter activity of 
pSV-Luc, pNSE-Luc. The plasmids were transfected into mNSCs, N2a, C6 cells. 
pDNA/carrier complexes are prepared at the N/P ratio of 5 which is optimal to 
gene transfer with low toxicity. We transfected three groups including control, 
pSV-Luc and pNSE-Luc. Control group is transfected only carrier PEI with the 
same concentration. In mNSCs, luciferase expression with NSE promoter was 
higher than with SV promoter which has moderate expression characteristics 
(Figure 2A, B). N2a cells had the same luciferase activity (Figure 2C) that 
pNSE-Luc showed two folds increases compared to pSV-Luc. However, in C6 
glioblastoma cells, there was no difference of luciferase expression between 
pSV-Luc and pNSE-Luc (Figure 2D). From the results, we confirmed that NSE 
promoter induced high gene expression in various neuronal cells and could be 
used for tissue target promoter. Moreover NSE promoter is not restricted in 
neurons because it is also active in neural stem cells.
17 
 
 
Figure 2. Luciferase expression in various neuronal cells. Plasmids were 
transfected into mNSCs (mouse neural stem cell), N2a (neuroblastoma cells), 
C6 (glioblastoma cells). Control means transfected only carrier PEI. 
pDNA/carrier complexes were prepared at a 5:1 N/P ratio. Plasmids transfected 
cells were incubated for 48 hours in normoxia conditions. Luciferase level was 
measured by luciferase assay. pNSE-Luc transfected group showed 2 folds 
higher expression level than pSV-Luc group in both mNSC (A) and N2a (C). 
(B) Transfected mNSCs IVIS image. However, C6 glial cells showed similar 
expression level in pSV-Luc and pNSE-Luc transfected groups (D).  
18 
 
3. Luciferase expression in differentiated neurons. 
NSE promoter is responsible for high expression level in differentiated 
neurons because NSE appears during neurogenesis and abundant in matured 
neurons.19 NSE protein is produced originally in neuroendocrine and its 
endogenous mRNA level is higher in differentiated PC12 neuroendocrine cells 
than undifferentiated PC12 cells.12,14 PC12 cells were differentiated using nerve 
growth factor (NGF) 20 and confirmed the neurite outgrowth (Figure 3C). In 
NGF-differentiated PC12, luciferase expression level induced by pNSE-Luc 
was higher than un-differentiated PC12, approximately 5 folds (Figure 3A). 
Because NSE is correlated with the differentiation state of neuronal cells, we 
measured the luciferase activity of gradually differentiated mNSCs treated the 
retinoic acid. 1μM of retinoic acid is optimal concentration 21 for differentiation 
and diluted to 0.1μM, 0.01μM. Untreat means treated only DMSO due to 
retinoic acid is dissolved in DMSO to use. It takes 7 days until differentiation 
and has long branching processes morphological appearance (Figure 3D). 5 
days after treating RA, we transfected plasmids into cells and allowed the 
luciferase gene 48 hours to express. Luciferase expression with NSE promoter 
in 1μM retinoic acid-differentiated mNSCs is much higher than control mNSCs 
(Figure 3B). In differentiated mNSCs treated 1μM retinoic acid, pNSE-Luc 
showed up to 5.2 folds higher luciferase expression than pSV-Luc, 20.4 folds 
higher than untreated-RA mNSCs. These results represent NSE promoter is 
more active in differentiated state. 
19 
 
 
20 
 
 
Figure 3. Luciferase activity of NSE promoter in differentiated cells. PC12 cells 
have the differentiation ability upon nerve growth factor (NGF). Differentiated 
PC12 has higher level of endogenous NSE mRNA and protein than 
undifferentiated PC12. Luciferase level of pNSE-Luc transfected differentiated 
PC12 was 5 folds higher than undifferentiated PC12 (A). Morphological 
appearance after 7 days of treating NGF (C). Differentiation of mNSCs was 
induced retinoic acid (RA). Immunostaining of mNSCs treated 1μM, 0.1μM, 
21 
 
0.01μM gradually and untreated RA. anti-Luc (1:1000, sigma), 
anti-microtubule-associated protein-2 (MAP-2, 1:500, abcam) antibodies was 
used (D). Since NSE protein is abundant in matured neurons, luciferase level in 
differentiated mNSCs treated 1μM RA was 20.4 folds higher than untreated-RA 
mNSCs (B). NSE promoter activity was also 5.2 folds higher compared to SV 
promoter in 1μM RA-differentiated mNSCs.  
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4. Luciferase expression under normoxia and hypoxia 
conditions. 
To increase gene expression under ischemic microenvironment following 
injury, hypoxia inducible gene expression system was constructed. To regulate 
gene expression transcriptionally, promoter and enhancer was used to control 
gene expression.22 Epo gene is induced under hypoxia conditions.15 In addition 
to neuron target promoter, Epo enhancer was used to hypoxia-inducible 
neuron-specific dual effects. To construct pEpo-NSE-Luc, Epo enhancer was 
inserted into upstream of NSE promoter. pNSE-Luc, pEpo-NSE-Luc was 
transfected into mNSCs and cultured under normoxia or hypoxia conditions for 
48 hours. Luciferase expression level of plasmids including Epo enhancer was 
3.2 folds higher than plasmids without Epo enhancer in hypoxia conditions 
(Figure 4A). Compare to pNSE-Luc which is absent Epo enhancer, 
pEpo-NSE-Luc also showed approximately 3.4 folds of luciferase expression. 
Moreover, pEpo-NSE-Luc transfected group represents similar gene expression 
level as pNSE-Luc transfected cells in hypoxia. It suggests that gene expression 
was regulated to express in hypoxia condition and limited in normal condition. 
To confirm the pEpo-NSE-Luc activity in differentiated neurons, mNSCs was 
treated 1μM RA for 7days. 5days after differentiation, pEpo-SV-Luc and 
pEpo-NSE-Luc was transfected. Luciferase level of pEpo-NSE-Luc is higher in 
differentiated mNSCs than undifferentiated state (Figure 4B). In differentiated 
mNSCs, pEpo-NSE-Luc showed 14.1 folds higher luciferase than pEpo-SV-Luc 
that only has promoter difference. Combination of Epo enhancer and NSE 
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promoter demonstrated dual specific effect in targeted-tissue under hypoxic 
conditions. 
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Figure 4. Luciferase level of pNSE-Luc, pEpo-NSE-Luc transfected mNSCs. 
Transfected cells were incubated for 48 hours under normoxia or hypoxia 
conditions. Plasmids including Epo enhancer increased luciferase expression 
compared to pNSE-Luc approximately 3.2 folds higher. pEpo-NSE-Luc 
transfected cells showed 3.6 folds higher luciferase expression under hypoxia 
than normoxia conditions (A). (B) shows luciferase expression in differentiated 
and undifferentiated cells transfected pEpo-SV-Luc, pEpo-NSE-Luc. In 
differentiated mNSCs, pEpo-NSE-Luc transfected cells showed higher 
luciferase expression compared to pEpo-SV-Luc only difference in promoter. 
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5. VEGF expression under normoxia and hypoxia conditions. 
 VEGF is considered to have therapeutic effects that neuroprotection and 
angiogenesis. Through mitogen-activated protein kinase (MAPK) pathway, 
VEGF promotes the survival and growth of neurons.7,23 In order to express 
VEGF gene using hypoxia-inducible neuron-specific vector, luciferase fragment 
of pNSE-Luc, pEpo-NSE-Luc was replaced VEGF gene (Figure 5). To confirm 
the expression of VEGF using dual specific vector system, RT-PCR is 
performed. pEpo-NSE-Luc transfected group showed the best amplified band 
under hypoxia conditions (Figure 6A). Epo enhancer increased the expression 
of VEGF gene under hypoxia conditions mimic ischemic injured 
microenvironment. Since VEGF is secretary growth factor, cell culture medium 
was collected and secreted VEGF is measured using VEGF antibody detection. 
VEGF expression level is higher in pEpo-NSE-Luc transfected hypoxic mNSCs 
(Figure 6B). The results suggested that the highest VEGF gene mRNA and 
protein in hypoxic conditions is the effect of Epo enhancer and NSE promoter 
activity.  
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Figure 5. Structure of pSV-VEGF, pNSE-VEGF, pEpo-NSE-VEGF plasmids. 
Luciferase gene was substituted for VEGF gene from pSV-Luc, pNSE-Luc, 
pEpo-NSE-Luc plasmids using HindIII and BamHI restriction enzyme sites.  
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Figure 6. Gel electrophoresis after RT-PCR. Isolated RNA was converted to 
cDNA and amplified. pEpo-NSE-VEGF transfected mNSCs showed the best 
amplified band under hypoxic conditions (A). Using Enzyme-linked 
immunosorbent assay, secreted VEGF was measured (B). Like luciferase 
reporter gene, VEGF gene expressed higher under hypoxic conditions. 
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6. Gene expression in spinal cord injury models 
 To evaluate the expression level of luciferase gene in vivo, pSV-Luc, 
pNSE-Luc, pEpo-NSE-Luc was directly injected to spinal cord following injury. 
Construction of spinal cord injury model was performed as previous state in 
Materials and Methods. After 10 minutes of clip compression to T9 level, 
plasmids were directly injected into caudal to injury site at the N/P ratio of 5. 
After 48 hours, tissue was extracted and performed luciferase assay. The 
expression level of luciferase was the highest in pEpo-NSE-Luc group among 
four groups including control due to the role of Epo enhancer in ischemic 
condition of injured spinal cord. Expression level of pNSE-Luc was higher than 
pSV-Luc. There results demonstrated the activity of NSE promoter and Epo 
enhancer in vivo.    
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Figure 7. Luciferase expression in injured spinal cord. pDNA/PEI complex was 
directly injected to spinal cord following clip suppression for 10 minutes. 
pEpo-NSE-Luc showed the highest gene expression. 
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7. Proliferation effect of VEGF 
 Since VEGF is well known for neuroprotective effect, therapeutic effect was 
confirmed by evaluating cell proliferation in vitro. Cells were transfected 
pEpo-NSE-Luc and cultured under normoxia or hypoxia condition for 24, 48, 
72 hours. Control group which is transfected only carrier showed no significant 
effect of proliferation for 72 hours. However, the absorbance value of cells at 
490nm showed the higher level under hypoxia than normoxia (Figure 8).  
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Figure 8. Proliferation effect of hypoxia-inducible neuron-specific VEGF. MTT 
assay determined cell viability under certain circumstances. pEpo-NSE-VEGF 
transfected cells proliferated up to 7.2-fold increase in hypoxia compared with 
6.4-fold increase in normoxia by control contained only PEI carrier. (N : 
normoxia, _H : hypoxia)  
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IV. DISCUSSION 
This study aimed specific expression of therapeutic gene in neuronal cells. In 
gene therapy, there are two ways to target the tissue. One is modifying viral 
vector to have tissue tropism. The other is using promoter to regulate gene 
expression in transcriptional level. To target the neuronal cells, we used NSE 
promoter. NSE protein is originally expressed in neuroendocrine and increased 
during neurogenesis. However, NSE promoter is active also in neural stem cells 
not only in matured neurons. It means NSE promoter can target various 
neuronal cells under developing stages. In order to test the capacity of 
neuron-specific promoter, we transfected pSV-Luc, pNSE-Luc to various 
neuronal cells. In mNSCs and N2a neuronal cells, pNSE-Luc showed higher 
luciferase expression than pSV-Luc. In contrast, luciferase activity introduced 
by pSV-Luc and pNSE-Luc showed no difference in C6 glial cells. PC12 cells 
that usually used for studying neuronal differentiation due to its ability to 
differentiate upon nerve growth factor 20 were transfected with pNSE-Luc. 
Differentiated-PC12 cells showed more than 5 times higher luciferase 
expression than undifferentiated-PC12 cells. In mNSCs, as cells differentiated 
upon retinoic acid concentration, so did the expression of luciferase. It showed 
the highest luciferase expression in 1μM RA treated mNSCs with pNSE-Luc 
transfection. In immunostaining, morphology of differentiated mNSCs 
aggregated and formed a mass. The number of neurites was increased and 
showed long neurite outgrowth.21 Following confirm the NSE activity, Epo 
enhancer was inserted into the upstream of NSE promoter. 
 In order to increase the gene expression in ischemic injury site, we used Epo 
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enhancer which is induced under hypoxia condition. We constructed combined 
vector system pEpo-NSE-Luc to dual-specific gene expression. Epo is a 
hormone which regulates erythropoiesis. Epo synthesis is activated when 
exposed to low blood oxygen by binding of hypoxia-inducible factor-1 (HIF-1) 
to Epo gene enhancer. Therefore, Epo enhancer has been used to increase 
reporter gene by hypoxia induction.15,16 pEpo-NSE-Luc transfected group 
showed the best expression under hypoxia conditions compared with normoxia 
or pNSE-Luc. In the case of differentiated mNSCs, luciferase level of 
pEpo-NSE-Luc transfected group is higher than undifferentiated mNSCs. Also, 
pEpo-NSE-Luc transfected group in both differentiated cells and 
undifferentiated cells showed higher luciferase expression compared with 
pEpo-SV-Luc which is only different in promoter. It means that overexpression 
in neuronal cells can take place at the injury site. Besides Epo enhancer, there 
are other ways to increase reporter gene under hypoxia such as pRTP801 
promoter, oxygen-dependent degradation (ODD) domain and Epo 
3’-untranslated region (UTR).24-26 However, Epo enhancer has better activity 
and induced more expression in previous reports.10,24-29 Also, enhancer is not 
limited in orientation and location unlike promoter.22 Therefore, 
enhancer-promoter combined vector system could show dual specific effect.  
Instead of luciferase gene, VEGF therapeutic gene was cloning to downstream 
of Epo enhancer and/or NSE promoter. Amplified mRNA and secreted VEGF 
quantity was measured by RT-PCR, ELISA. pEpo-NSE-VEGF transfected 
group showed the highest expression level under hypoxia condition expectably. 
VEGF is expressed in neurons, glial cells and has autocrine effect on neurons 
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and paracrine action through interaction between neurons and glial cells.5 
VEGF and VEGF receptor-2 are inducible under hypoxic condition and exert 
neuroprotective effect in response to hypoxia, oxidative stress through 
mitogen-activated protein kinase (MAPK) and phosphatidyloinositol 3’-kinase 
(PI3K)/Akt signal transduction system.23,30 VEGFR-2 is also expressed on the 
surface of spinal cord in vivo.31 Under stress condition like ischemia, oxidative 
stress, multiple molecular pathway lead to neuroprotective action by inhibiting 
apoptosis, stimulating neurogenesis.32-34 VEGF induce vessel formation that 
restores blood oxygen delivery so that increases cell survival and 
proliferation.35-37 However, exogenously delivered VEGF affect physiological 
impact in non-ischemic and normal tissue so that results in formation of 
vascular tumor.38 Therefore, it is necessary to restrict gene expression in 
ischemic tissue to avoid side effect.  
In addition to Epo enhancer which is inducible under hypoxia condition, using 
neuron target promoter makes it possible to express therapeutic gene in neurons. 
With this combined vector system, dual-specific gene expression can be a 
useful gene therapy tool.  
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V. CONCLUSION 
 
Spinal cord injury occur a complex interaction between neuron and glial cells 
resulting in dysfunction. At the SCI site, neural precursor cells were 
predominantly differentiated into astrocyte rather than oligodendrocyte. Since 
reactive astrocyte exhibits negative effect in injury site, it is necessary to 
regenerate neuron specifically. To target the neuron, NSE promoter was used in 
this study. With neuron-specific promoter, reporter gene was expressed in 
neuronal cells not in glial cells. Also, it showed more gene expression 
depending on the differentiated state of mouse neural stem cells. It is 
contributed to that NSE is abundant in matured neuron. In SCI, ischemia is an 
important cause of secondary injury because neurovascular damage reduced 
oxygen level. Therefore, in addition to neuron-specific promoter, 
hypoxia-inducible vector would be increase gene expression. For that, Epo 
enhancer was used to combine NSE promoter. The results showed that Epo 
enhancer and NSE promoter dual specific vector increases cell proliferation and 
gene expression under hypoxic condition both in vitro and in vivo. Using this 
combined hypoxia-inducible neuron-specific promoter vector system, 
therapeutic gene can exert dual specific effect.  
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Abstract (in korean) 
 
저산소 유도 신경 특이적 프로모터 벡터를 이용한 효율적인 
혈관내피성장인자 발현 
 
<지도교수  하 윤> 
 
연세대학교 대학원 의과학과 
 
윤 여 민 
 
 
 척수손상은 기계적인 1차 손상 이후 허혈성 조직환경이나 
염증반응에 의해 세포사멸, 혈관손실, 탈수초 같은 2차 손상이 
발생한다. 신경혈관 손상은 신경세포로의 산소전달을 감소시켜 
산소에 대한 의존도가 높은 신경세포가 큰 타격을 받게 된다. 손상 
후 이러한 허혈성 조직 환경은 손상을 회복하기 위해 신경 
줄기세포에서 신경교세포로 분화가 이루어지지만 주로 성상교세포로 
분화가 되고, 손상으로 인한 허혈성 환경에서의 성상교세포는 
신경혈관의 기능을 약화시키게 된다. 때문에 척수손상을 치료하기 
위해서 신경교세포보다 신경세포에서 선택적으로 많이 치료유전자를 
발현시킬 수 있는 조절 가능한 벡터 시스템이 필요하다. 때문에 본 
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연구에서는 신경세포에 많이 존재하는 뉴런특이적에놀라아제를 
프로모터로 이용하여 신경세포에서 유전자 발현효율을 높였다. 
뉴런특이적에놀라아제는 분화된 신경세포에서 많이 존재하므로 
신경세포가 분화됨에 따라 이 프로모터에 의한 유전자 발현이 
증가하다는 것을 확인하였다. 또한 손상조직의 허혈성 조건에서 
발현을 더 유도시키기 위해 저산소조건에서 많이 발현되는 
에리스로포에틴을 인핸서로 이용하여 저산소조건에서 유전자가 더 
발현됨을 확인하였다. 에리스로포에틴 인핸서와 
뉴런특이적에놀라아제 프로모터를 결합한 벡터에서는 저산소 
조건에있는 신경세포에서 유전자가 가장 많이 발현되었다. 이러한 
유전자 발현 시스템을 확립한 뒤, 척수손상에 대한 치료유전자로서 
혈관생성과 신경보호기능이 있는 혈관내피성장인자 또한 
저산소환경의 신경세포에서 발현량이 증가함을 확인하였다. 저산소 
유도 신경 특이적 유전자 발현 시스템을 이용해서 신경세포를 
타겟으로 치료유전자의 기능을 효율적으로 증가시킴으로 인해 
신경손상에 대한 다양한 유전자치료에 활용할 수 있을 것이라 
생각된다.  
 
 
 
---------------------------------------------------------------------------------------------------------- 
핵심되는 말 : 신경 특이적 프로모터, 저산소 유도 유전자 발현, 뉴런
특이적에놀라아제, 에리스로포이틴, 혈관내피성장인자 
